Objective: To establish feasibility of initiating electrical stimulation treatment of wrist extensors and flexors in patients early after stroke to prevent muscle contractures and pain. Design: Feasibility randomized controlled trial with economic evaluation. Setting: A specialist stroke unit in Nottinghamshire. Subjects: A total of 40 patients recruited within 72 hours post-stroke with arm hemiparesis. Interventions: Participants were randomized to receive usual care or usual care and electrical stimulation to wrist flexors and extensors for 30 minutes, twice a day, five days a week for three months. Initial treatment was delivered by an occupational therapist or physiotherapist who trained participants to selfmanage subsequent treatments. Measures: Measures of feasibility included recruitment and attrition rates, completion of treatment, and successful data collection. Outcome data on wrist range of motion, pain, arm function, independence, quality of life, and resource use were measured at 3-, 6-, and 12-months post-randomization. Results: A total of 40 participants (of 215 potentially eligible) were recruited in 15 months (20 men; mean age: 72 (SD: 13.0)). Half the participants lacked mental capacity and were recruited by consultee consent. Attrition at three-month follow-up was 12.5% (death (n = 2), end-of-life care (n = 2), and unable to contact (n = 1)). Compliance varied (mean: 65 (SD: 53)) and ranged from 10 to 166 treatments per patient (target dosage was 120). Data for a valid economic analysis can be adequately collected.
Introduction
Impaired arm function is a permanent and disabling problem for an estimated 40% of stroke survivors. 1, 2 In the presence of persistent paresis, arm muscles atrophy rapidly, and patients, particularly those with spasticity and pain, are at an increased risk of developing painful muscle contractures (fixed joint deformities). 3 Prevalence of hand and wrist contractures is unknown, but contractures can become established as early as six weeks after stroke 3 and as many as 60% of care home dwelling stroke survivors develop at least one contracture within a year after a stroke. 4 It is possible that one cause for contracture is the lack of adequate upper limb therapy input, 1, 5, 6 that is, on average, patients spend between 0.9 and 7.9 minutes per physiotherapy session on arm rehabilitation. 7 Evidence suggests that early initiation (24 hours post-stroke) of rehabilitation interventions and high intensity of treatment can enhance the chances of neurological recovery; [8] [9] [10] [11] [12] however, there is also the potential for risk of harm. 13, 14 For those patients unlikely to make functional gains, prevention of complications such as pain and contractures (fixed joint deformity) should be the focus of therapeutic interventions, and there is some evidence that treatment with electrical stimulation is of potential value. [15] [16] [17] [18] Previous pilot trials of electrical stimulation have only focussed on stimulation of the extensor muscles and have not stimulated the flexor muscle group but have demonstrated some benefit in terms of slowing the rate of deterioration and, in some cases, facilitating recovery; however, effect sizes were small. [16] [17] [18] These studies concluded that the treatment was not given long enough and premature discontinuation of therapy may have reduced any potential therapeutic effect. No extended trials have been conducted. Furthermore, the muscles at risk of shortening are the wrist and forearm flexors, and the most effective method of loading the soft tissue structures of the flexors, in patients who are unable to fully activate their muscles, is by electrically stimulating these muscles.
The aim of this study was to evaluate the feasibility of conducting a future definitive randomized controlled trial of the efficacy and cost-effectiveness of early, intensive electrical stimulation to prevent wrist joint deformities/muscle contractures, weakness, and upper limb pain after stroke by stimulating the wrist flexors and extensors reciprocally.
Methodology
This single-centre, unblinded randomized controlled trial was approved by the National Research Ethics Service, East Midlands Nottingham (UK) Research Ethics Committee (ref: 15/EM/0006) and was registered with ClinicalTrials.gov (identifier: NCT02324634). The study was hosted by Nottingham University Hospitals National Health Service (NHS) Trust and coordinated by the University of Nottingham (the research sponsor). The full study protocol has been previously published in the British Medical Journal 19 and is briefly described below.
Patients admitted to Nottingham University Hospitals' stroke unit were eligible for participation if recruitment could be conducted within 72 hours of stroke. All participants were required to provide written informed consent, and an 'aphasia friendly' version of the information sheets and consent form were available for those with communication difficulties. In cases where it was not possible to obtain informed consent from the patient due to communication and/or cognitive difficulties, consultee consent was obtained from the patient's relative. Consenting participants were independently randomized into an intervention or a control group using a telephone randomization service. Minimization was based on age, sex, side of stroke, and severity of arm weakness (as measured by the NIHSS 20 arm sub score).
Usual care control
Participants randomized to the control group did not receive electrical stimulation therapy but received all usual care (which did not include the use of surface neuromuscular electrical stimulation). It was not possible to collect data on the nature or volume of usual care.
Intervention treatment
Participants randomized to the treatment group received treatment with electrical stimulation in addition to their routine care. Treatment with electrical stimulation was delivered using a two-channel constant current stimulator (maximum output: 100 mA, pulse width: 450 μs, and a frequency between 40 and 60 Hz as per participant preference)* A . The current intensity was increased to produce an alternating contraction of the flexors and extensors using a flex-hold-extend-hold pattern, ensuring that a pure movement was produced with no/minimal ulnar or radial deviation. A single stimulation and hold cycle lasted 20 seconds, and this was cyclically repeated for 30 minutes (40 cycles of movement in a full treatment session). Treatment continued twice a day, five days a week (Monday to Friday), for a total period of three months.
The total possible number of electrical stimulation treatments (as per protocol) was 120 treatment sessions.
The motor points for stimulation were selected to produce reciprocal flexion and extension through full range of movement. 21 The first treatment was provided by a qualified (NHS band 5 or above) physiotherapist or occupational therapist who was trained to identify the motor points for electrical stimulation. Following the initial treatment, the skin was marked with a skin-safe marker pen to show the correct area to place the electrodes for future treatments, and the electrical stimulation device was locked to the selected settings. After the initial session, clinical staff (e.g. rehabilitation support workers, nursing support staff, or healthcare assistants) assisted the patient to apply the electrode pads to the pre-marked motor points and switch on the device with the pre-stored treatment setting (this took between 2 and 5 minutes) for subsequent treatments. Prior to hospital discharge, the patient and/or nominated carer were taught by a therapist on how to self-manage the treatment.
Outcome measures
The primary outcomes related to feasibility aims are as follows:
• • Recruitment/participation and exclusion rates.
• • Completion/attrition rates.
• • Compliance/adherence to treatment protocol.
• • Consultee consent rates.
• • Outcome measure completion rates.
The secondary outcomes were demographic characteristics (age, gender, ethnicity, and socioeconomic status), stroke characteristics (date, type, and side of stroke), cognitive status (Montreal Cognitive Assessment (MoCA) 22 ), and pre-morbid function state (Nottingham Extended Activities of Daily Living (NEADL) 23 ), which were collected at baseline. In addition, participants completed the following assessments at 3, 6, and 12 months:
• • Independence in daily activities (Barthel ADL Index score 24 and modified Rankin Scale (mRS) 25, 26 ). • • Pain in the affected arm (Scale of Pain Intensity (SPIN) 27 ). • • Spasticity (was measured as stretch induced activation of muscles as described in Malhotra et al. 3 ).
• • Arm function (Action Research Arm Test
(ARAT) 28 ).
• • Stroke-related quality of life (Stroke Specific
Quality of Life Scale (SS-QOL) 29 ). • • Health status (EuroQol-5D (EQ-5D)). 30 • • Patient resource use questionnaire.
• • Carer strain (Caregiver Strain Index (CSI)) 31 completed by the participant's nominated carer.
Baseline assessments were completed on the stroke unit by the patient's bedside, and 3-, 6-, and 12-month follow-ups were completed in the community at the patient's discharge destination (e.g. home or care home). 
Statistical analysis and reporting

Results
Recruitment began on 1 June 2015. Of 215 potentially eligible patients, 40 were recruited in 15 months (20 men; mean age: 72 years (SD: 13.0); Figure 1 ); 22 potentially eligible patients declined to participate. Half of the participants (n = 20) lacked the mental capacity to provide informed consent and were therefore recruited by consultee consent. All participants were recruited within 72 hours following a first stroke, and baseline characteristics are summarized in Table 1 . The treatment groups were well-matched in terms of NIHSS arm score, but participants in the control group had higher stroke severity (median NIHSS 15) compared to the electrical stimulation group (median NIHSS 9). Attrition at 3-month follow-up was 12.5% (5/40) and at 12-month follow-up was 32.5% (13/40). Reasons for attrition are summarized in the CONSORT flow diagram (Figure 1 ). The number of treatments received ranged from 10 to 166 with a mean of 64.5 (SD: 53). Five participants used the device in excess of the standard protocol (120 treatment sessions). Reasons for participants not receiving the target number of treatments included the electrical stimulation device being locked in the hospital bedside cabinet by stroke unit staff or placed out of reach of the patient, illness that prevented engagement in any rehabilitation for a period of time, or the participant regaining full functional use of the upper limb and therefore discontinuing treatment. There was also one incident of protocol violation early on in the study, whereby a therapist did not agree with the concept of stimulating the flexor muscles and instead fabricated a thermoplastic static resting splint for the limb. The 3-, 6-, and 12-month outcome measure completion rates of the participants by treatment allocation are summarized in Table 2 .
Of the 26 patients, 14 had an NIHSS arm score of zero (i.e. a marker of return in arm function), 4 had a score between one and three (a marker for some arm function), and 8 had a score of four (a marker for no arm function).
Majority of participants had already developed spasticity (as defined by Malhotra et al. 3 It was not feasible to use the SS-QOL measure. The SS-QOL is a lengthy questionnaire-based assessment that relies heavily on the ability of the patient to understand verbal or written communication and select their chosen response to each question from a list of options. The sample population in this study included patients who were not yet fully conscious or were drowsy in the early days following their stroke. The sample also included patients with receptive, expressive, and global aphasia.
The patient resource collection was acceptable to patients. Completion rates fell over time, but only slightly, and did not give the team cause for concern that this measure posed an unacceptable patient burden. The time point that caused most problems with completion was at baseline. It was felt this collection point could be sacrificed in favour of cost outcome comparisons with and without the intervention using an incremental effectiveness approach (ICER).
The intervention cost was determined by taking the cost of the electrical stimulation machine discounted at 3.5% (as recommended in the Green Book by Her Majesty's Treasury 32 ) over five years to yield an annual cost. In total, 12 electrical stimulation machines were used in this study, and it was assumed that for each patient using the machine, they had a spare set of batteries and electrodes. The cost of the intervention also included the therapists' time to receive training on how to deliver the intervention (4 × therapists at Band 6 B for 1 hour) and Band 3 therapist support staff time to receive training on how to deliver the intervention (4 × support staff for 30 minutes). The cost included the initial treatment time with the intervention by a Band 6 therapist for 1 hour and further treatments delivered by support staff at Band 3 for 10 minutes per treatment (up to a total of three). The total costs of the electrical stimulation machines (discounted), replacement batteries, replacement electrodes, and the total costs of staff time were calculated and further divided by the number of electrical stimulation patients (20) to provide an estimate of the electrical stimulation intervention cost per patient. This was £37.90 per patient (see health economics Supplemental material for details of how this figure was calculated).
The study was focused on establishing the complete NHS and societal costs including those costs incurred by the patients and their families between the two groups, which included primary and secondary care costs associated with their arm function, out of pocket expenses, and any effects on employment for either the patient or their carers. This was completed at baseline, 3-, 6-, and 12-month follow-ups. Table 3 displays the mean QALYs up to 12 months by the two arms. The results show that the intervention arm had higher QALY gains when compared to the usual care arm; however, the incremental difference was small, and both groups improved over time. Table 4 displays the resource use costs of electrical stimulation and usual care up to 12 months. The usual care arm had higher costs compared to the electrical stimulation arm, from both the health service (NHS) and societal perspective. Electrical stimulation was therefore associated with a lower consumption of resources and consequently lower costs, compared to those in the usual care arm.
A bootstrap analysis was done based on the complete case analysis, a method to infer about likely population data from a sample set (electrical stimulation n = 11; usual care n = 6).
The scatter diagrams are presented in Figure 2 which represent the results from an NHS perspective and a societal perspective. The results show that the bootstrap replications cover all four quadrants of the cost-effectiveness plane, indicating there is uncertainty around the interventions overall cost-effectiveness, as would be expected in a feasibility pilot study. The majority of the points on the cost-effectiveness plane were below the x-axis, indicating that electrical stimulation was less costly than the standard arm. The findings show that at 12 months, the electrical stimulation arm dominates the usual care arm, with higher outcomes and lower costs.
Discussion
This study was able to demonstrate that it is feasible to recruit patients early after stroke (within 72 hours) and for physiotherapists and occupational therapists to initiate electrical stimulation treatment of the wrist and finger extensor and flexor muscles. Furthermore, once treatment was initiated, it was possible to continue to deliver treatment in a way that was compliant with the protocol. It is possible that the training protocol and the educational booklets contributed to the enhanced compliance. However, there will be a need to adjust sample size by 32.5% if the identified primary end point is 12 months. In this feasibility study, 17% of eligible patients were enrolled. This high number of patients not included was not only due to the exclusion criteria but also due to the fact that the local specialist stroke service is an active research site with competing trials, and many studies do not permit a patient to enrol in more than one active research trial. This was a barrier to recruitment at this site and is a factor that would need to be considered when selecting potential study sites for a future multi-centre trial. A common barrier for electrical stimulation of flexors is the fear that treatment with electrical stimulation could exacerbate spasticity. This study has demonstrated an important safety finding that treatment with electrical stimulation is unlikely to lead to spasticity or exacerbate spasticity. Furthermore, the electromyography (EMG), National Institute for Health Stroke Scale (NIHSS) arm score, and ARAT data demonstrated that it was possible for patients to have spasticity and yet still regain arm function during the trial.
An important aspect of this feasibility study was to determine the most suitable outcome measures for an ensuing definitive trial. The aim of the electrical stimulation intervention was to prevent painful muscle contractures which can lead to a permanent joint deformity. The primary outcome should therefore reflect this. The objective measurement of passive range of movement, stiffness and spasticity as measured by Malhotra et al. 3 was not considered feasible for use in a large multicentre trial due to complexity and cost of equipment, need for training, and the possibility of equipment failure. A standard range of movement goniometer or measurement app for use on a tablet or mobile phone would be more feasible for use in any subsequent trial.
The SPIN was a feasible measure for use in this patient population to capture severity of pain in the affected arm. The NIHSS, Barthel ADL Index, mRS, ARAT, and Euro Qual 5D (five-level version) were feasible for measuring secondary outcomes in this patient population. The Stroke Specific Quality of Life scale was not a suitable measure for this patient population. The carer strain index was not suitable for completion at baseline, and completion rates in general were low. In a future study, it is recommended that carer burden is captured within the resource use questionnaire to reduce duplication and assessment burden. The MoCA was not feasible for use with all of the sample population as it requires the ability to communicate and also includes some pen and paper drawing tasks. The sample population in this study included patients who were not yet fully conscious or were drowsy in the early days following their stroke. Those participants who had severe weakness in their usually dominant hand and arm were unable to complete the drawing and written tasks in the MoCA.
The feasibility health economic evaluation demonstrated that the resource use questionnaire and EQ5D-5L could be used to capture economic data to determine cost-effectiveness of the electrical stimulation intervention in a definitive trial and that they were acceptable to the patient group. They yield some promising early results in terms of an economic comparison of the treatment options. It was felt the baseline data collection point for resource could possibly be sacrificed to reduce patient burden, and an ICER calculated between the two arms of a trial. Early post-stroke is a traumatic time for patients and families, and trying to establish patient and carer resource use at this time is problematic.
In this feasibility study, limited resources meant that it was not possible to have an additional outcome assessor who was blinded to treatment allocation. The outcome measures were objective and were unlikely to have been biased; however, future studies should use independent assessors if possible.
Furthermore, there are limitations involved in interpreting the data due to the small sample size and therefore no definitive conclusions on efficacy can be drawn from this small sample.
Arm weakness and post-stroke complications pose a considerable threat to the independence and productivity of stroke survivors. This feasibility study was important because it addressed the needs of a significant proportion of severely disabled stroke patients with a poor prognosis for recovery and at a high risk for secondary complications. The ESCAPS feasibility study has data to inform the design of a multi-centre randomized controlled trial to evaluate the efficacy and cost-effectiveness of early electrical stimulation to the wrist flexors and extensors. A suitably powered trial with blinded outcome assessors is warranted to determine effectiveness and cost-effectiveness of the intervention in preventing painful contractures to the wrist and hand post stroke.
